Vor Biopharma Inc.
VOR
$2.17
-$0.03-1.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.40M | 6.59M | 5.96M | 6.70M | 7.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 243.55M | 33.29M | 31.31M | 28.51M | 29.04M |
| Operating Income | -243.55M | -33.29M | -31.31M | -28.51M | -29.04M |
| Income Before Tax | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M |
| EBIT | -243.55M | -33.29M | -31.31M | -28.51M | -29.04M |
| EBITDA | -241.51M | -32.47M | -30.45M | -27.66M | -28.17M |
| EPS Basic | -12.56 | -0.26 | -0.44 | -0.40 | -0.41 |
| Normalized Basic EPS | -7.70 | -0.16 | -0.27 | -0.25 | -0.25 |
| EPS Diluted | -12.56 | -0.26 | -0.44 | -0.40 | -0.41 |
| Normalized Diluted EPS | -7.70 | -0.16 | -0.27 | -0.25 | -0.25 |
| Average Basic Shares Outstanding | 125.27M | 124.82M | 70.02M | 68.47M | 68.30M |
| Average Diluted Shares Outstanding | 125.27M | 124.82M | 70.02M | 68.47M | 68.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |